Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2023 Earnings Call Transcript
Taysha Gene Therapies, Inc. beats earnings expectations. Reported EPS is $0.92, expectations were $-0.09.
Taysha Gene Therapies Inc. (TSHA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 18,472,503 | $32,696,330 | 0.51% | |
| 2. | VenBio Select Advisor Kurt Von Emster | 4,355,555 | $7,709,332 | +11% | 0.1% |
| 3. | Baker Bros. Advisors Julian Baker And Felix Baker | 4,004,756 | $7,088,418 | +60% | 0.08% |
| 4. | Eversept Partners Kamran Moghtaderi | 3,780,714 | $6,691,864 | +122% | 0.58% |
| 5. | Tybourne Capital Management Eashwar Krishnan | 3,700,000 | $6,549,000 | +147% | 0.97% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.63 | 100,000 | Large Shareholder | 16,566,667 | 2023-11-17 | Filing | |
| $0.90 | 16,466,667 | Large Shareholder | 16,466,667 | 2023-08-16 | Filing | |
| $0.90 | 388,889 | Director | 999,381 | 2023-08-16 | Filing | |
| $0.90 | 388,889 | Director | 884,290 | 2023-08-16 | Filing | |
| $0.90 | 444,444 | Officer, Director | 1,535,545 | 2023-08-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.33 | 33,000 | Officer | 258,042 | 2023-08-24 | Filing | |
| $0.70 | 5,344 | 8,871,747 | 2023-07-13 | Filing | ||
| $0.71 | 80,528 | 8,877,091 | 2023-07-12 | Filing | ||
| $0.70 | 18,100 | Large Shareholder | 8,957,619 | 2023-06-23 | Filing | |
| $0.70 | 10,508 | Large Shareholder | 8,975,719 | 2023-06-22 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 22,439,124 | $39,717,250 | 0% | |
| 2. | 16,893,185 | $29,900,937 | 0.46% | |
| 3. | 10,412,872 | $18,430,783 | 1.26% | |
| 4. | 6,195,567 | $10,966,154 | 0% | |
| 5. | 2,912,861 | $5,155,764 | 0.57% |
News See All
5 Best Rising Penny Stocks To Buy
Monopar Therapeutics (NASDAQ:MNPR) recently jumped after the company reported positive preclinical data for its MNPR-101 program.
Hedge Funds Say These 5 Penny Stocks are Poised to Explode
Below you can find the list of 5 penny stocks that are poised to explode according to hedge funds.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q3 2023 Earnings Call Transcript
Operator: Good afternoon and welcome to the Taysha Gene Therapies Third Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.
Hedge Fund and Insider Trading News: Cathie Wood, Citadel LLC, Adage Capital Management, Hippo Holdings Inc (HIPO), Taysha Gene Therapies, Inc. (TSHA), and More
Cathie Wood extended her bet on Dutch payment processing company Adyen NV just after a growth slowdown sent the stock down by almost half to its lowest level in three years.
Hedge Fund and Insider Trading News: George Soros, Ray Dalio, Ken Griffin, Daniel Och, EDL Capital, Rokos Capital Management, Precigen Inc (PGEN), Sigilon Therapeutics, Inc. (SGTX), and More
George Soros has been branded as a bogeyman by the right wing for backing liberal causes around the globe.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2023 Earnings Call Transcript
Operator: Thank you for standing by. This is the conference operator. Welcome to the Taysha Gene Therapies First Quarter 2023 Earnings Conference Call.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2022 Earnings Call Transcript
Operator: Greetings, and welcome to the Taysha Gene Therapies Fourth Quarter and Full-Year 2022 Earnings Call. At this time, all participants are in a listen-only mode.
5 Popular Penny Stocks On Robinhood
In this article, we will discuss the 5 best penny stocks trending on Robinhood. If you want to explore similar stocks, you can read 11 Popular Penny Stocks On Robinhood.
8 Stocks in Eashwar Krishnan's Tybourne Capital Management Portfolio
In this article, we will take a look at some of the stocks in Eashwar Krishnan’s Tybourne Capital Management portfolio.